- Home
- DSM vs FHTX Comparison
DSM vs FHTX Comparison
Compare DSM & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSM
- FHTX
- Stock Information
- Founded
- DSM 1989
- FHTX 2015
- Country
- DSM United States
- FHTX United States
- Employees
- DSM N/A
- FHTX N/A
- Industry
- DSM Investment Managers
- FHTX Medicinal Chemicals and Botanical Products
- Sector
- DSM Finance
- FHTX Health Care
- Exchange
- DSM Nasdaq
- FHTX Nasdaq
- Market Cap
- DSM 280.8M
- FHTX 278.1M
- IPO Year
- DSM N/A
- FHTX 2020
- Fundamental
- Price
- DSM $5.94
- FHTX $4.97
- Analyst Decision
- DSM
- FHTX Strong Buy
- Analyst Count
- DSM 0
- FHTX 6
- Target Price
- DSM N/A
- FHTX $11.33
- AVG Volume (30 Days)
- DSM 161.7K
- FHTX 86.4K
- Earning Date
- DSM 01-01-0001
- FHTX 11-03-2025
- Dividend Yield
- DSM 3.97%
- FHTX N/A
- EPS Growth
- DSM N/A
- FHTX N/A
- EPS
- DSM N/A
- FHTX N/A
- Revenue
- DSM N/A
- FHTX $24,173,000.00
- Revenue This Year
- DSM N/A
- FHTX $43.75
- Revenue Next Year
- DSM N/A
- FHTX $1.27
- P/E Ratio
- DSM N/A
- FHTX N/A
- Revenue Growth
- DSM N/A
- FHTX N/A
- 52 Week Low
- DSM $4.69
- FHTX $2.95
- 52 Week High
- DSM $6.05
- FHTX $10.25
- Technical
- Relative Strength Index (RSI)
- DSM 75.94
- FHTX 45.28
- Support Level
- DSM $5.87
- FHTX $4.78
- Resistance Level
- DSM $6.00
- FHTX $5.58
- Average True Range (ATR)
- DSM 0.05
- FHTX 0.33
- MACD
- DSM 0.02
- FHTX -0.06
- Stochastic Oscillator
- DSM 84.62
- FHTX 17.76
About DSM BNY Mellon Strategic Municipal Bond Fund Inc.
BNY Mellon Strategic Municipal Bond Fund, Inc. is a diversified closed-end management investment company. Its investment objective is to seek to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.